Evogene Ltd. (TLV:EVGN)
358.20
-2.50 (-0.69%)
At close: Jan 9, 2026
Evogene Revenue
Evogene had revenue of $312.00K USD in the quarter ending September 30, 2025, a decrease of -82.63%. This brings the company's revenue in the last twelve months to $5.25M, down -26.75% year-over-year. In the year 2024, Evogene had annual revenue of $8.51M with 50.90% growth.
Revenue (ttm)
$5.25M
Revenue Growth
-26.75%
P/S Ratio
1.18
Revenue / Employee
$44.88K
Employees
117
Market Cap
31.22M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.51M | 2.87M | 50.90% |
| Dec 31, 2023 | 5.64M | 3.97M | 236.72% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | 753.00K | -994.00K | -56.90% |
| Dec 31, 2018 | 1.75M | -1.63M | -48.33% |
| Dec 31, 2017 | 3.38M | -3.16M | -48.30% |
| Dec 31, 2016 | 6.54M | -4.59M | -41.23% |
| Dec 31, 2015 | 11.13M | -3.38M | -23.31% |
| Dec 31, 2014 | 14.51M | -3.07M | -17.46% |
| Dec 31, 2013 | 17.58M | 509.00K | 2.98% |
| Dec 31, 2012 | 17.07M | 2.17M | 14.57% |
| Dec 31, 2011 | 14.90M | 2.34M | 18.61% |
| Dec 31, 2010 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.87B |
| Novolog (Pharm-Up 1966) | 1.97B |
| Ilex Medical | 917.10M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| BrainsWay | 162.56M |
| Bait Bakfar | 107.78M |
Evogene News
- 4 days ago - Evogene (EVGN) and Unravel Biosciences Partner to Tackle Neurological Diseases - GuruFocus
- 4 days ago - Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders - PRNewsWire
- 12 days ago - Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development - PRNewsWire
- 4 weeks ago - EverGen Infrastructure Corp. (EVGN:CA) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 7 weeks ago - EverGen Infrastructure Corp. (EVGN:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Evogene GAAP EPS of -$0.31 beats by $0.10, revenue of $0.31M misses by $0.34M - Seeking Alpha
- 7 weeks ago - Evogene Reports Third Quarter 2025 Financial Results - PRNewsWire